Olugbenga Olowokure

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

Bert H. O’Neil, Aaron J. Scott, W.W. Ma et al. · Annals of Oncology · 2015 · 140 citations · Full text

Oncology, Pancreatic Cancer, Gastrointestinal Oncology +9

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Trisha M. Wise‐Draper, Ganesh Moorthy, Mohamad A. Salkeni et al. · Targeted Oncology · 2017 · 112 citations · Full text

Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer

Jordan Kharofa, Michelle Mierzwa, Olugbenga Olowokure et al. · American Journal of Clinical Oncology · 2019 · 85 citations

Pulmonary metastases in pancreatic cancer, is there a survival influence?

Ayham Deeb, Sulsal Haque, Olugbenga Olowokure · PubMed · 2015 · 58 citations · Full text

Surgical Oncology, Pancreatic Cancer Metastases, Hepatology +12